Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety

Wei Wei(Zhujiang Hospital), Rong Guo(Sun Yat-sen University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Lie Zheng(Sun Yat-sen University), Ming Shi(Yanshan University), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhi‐Xing Guo(Sun Yat-sen University), Xiaojun Lin(Sun Yat-sen University), Minshan Chen(Sun Yat-sen University), Yong‐Fa Zhang(Sun Yat-sen University), Pei‐En Jian(Sun Yat-sen University), Yihong Ling(Sun Yat-sen University)
癌症：英文版
October 10, 2018
10.1186/s40880-018-0331-y
Cited by 189

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417